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Cytomegalovirus Viral Load
in the Colon and Risk of
Colectomy in Hospitalized
Patients With Inflammatory
Bowel Diseases
To the Editor:
We read with interest the article of
Lee et al1 describing the risk factors for
adverse outcomes in hospitalized patients
with ulcerative colitis (UC) with concur-
rent cytomegalovirus (CMV) colitis.
CMV reactivation and resolution can be
spontaneous in patients with UC regard-
less of antiviral therapy; however, incon-
sistencies between CMV detection
methods of various studies and criteria
for defining CMV positivity may be lead-
ing to these disparate findings.2,3 In the
study by Lee et al, CMV colitis
was defined by the presence of 1 or more
inclusion bodies on hematoxylin and
eosin staining or CMV immunohisto-
chemistry on colonic biopsies. The most
accurate approach for detection of clini-
cally significant CMV infection has not
been firmly established and guidelines dif-
fer in their recommendations.3,4 A recent
study using quantitative colonic PCR in
consecutive patients with UC undergoing
endoscopy in the setting of a moderate to
severe flare demonstrated a correlation
between higher viral load and resistance
to immunosuppressive therapy with sig-
nificant differences found when using
a cutoff viral load of .250 per milligram
tissue.5
We retrospectively evaluated the
association between CMV viral load in
colonic biopsies and rate of colectomy
following 1 and 6 months after CMV
detection in patients hospitalized for UC
(n ¼ 14) and Crohn’s colitis (n ¼ 4). A
total of 11 patients (58%) underwent co-
lectomy within 6 months; of these, 7
(37%) underwent colectomy at 1 month.
The only factor significantly associated
with colectomy at 6 months was a lower
albumin at admission (P ¼ 0.02). Median
colonic CMV copies per milliliter were
3647 (interquartile range [IQR], 1112–
14,907) for those undergoing colectomy
by 6 months and 991 (IQR, 95–1934)
among those not undergoing colectomy
(P ¼ 0.09; Fig. 1). When evaluating
quartiles of CMV copies per milliliter,
there was no significant difference in co-
lectomy rate across quartiles of the CMV
DNA copies, although this did steadily
increase (40%, n ¼ 2; 50%, n ¼ 2;
75%, n ¼ 3; 80%, n ¼ 4; P ¼ 0.62).
Antiviral therapy resulted in a nonsignifi-
cant trend toward colectomy prevention
during the 6-month follow-up period
with prevention in 40% (4/10) of those
treated compared with 0% of those
untreated (0/3); P ¼ 0.50.
Quantitative PCR of colonic tissue
for CMV DNA may be a useful method
for not only identifying but also assessing
the clinical significance of a concomitant
CMV infection. However, this method is
not ready for routine clinical use. To
validate the findings, further standardiza-
tion of such a testing method and
prospective studies in patients with ran-
domized therapeutic interventions are
required.
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FIGURE 1. CMV viral load in colonic biopsies (copies per milliliter) and 6 months colectomy rates
in patients with inflammatory bowel diseases (UC, n ¼ 14; Crohn’s disease, n ¼ 4).
